Skip to main content

Table 2 Evaluation of Mayo score, clinical response, clinical remission, endoscopic activity, and biochemical tests throughout treatment with anti-TNF therapy

From: Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)

  Baseline (n=374) Week 8 (n=352) Week 26 (n=296) Week 52 (n=291)
Partial Mayo score 5.75 ± 2.33 3.36 ± 2.37* 2.46 ± 2.26* 1.89 ± 2.25*
Mayo endoscopic subscore 2.53 ± 0.61 1.43 ± 0.97* 1.08 ± 1.10*
Full Mayo score 8.37 ± 2.48 3.9 ± 2.76* 2.88 ± 2.86*
Clinical disease activity
Remission 8 (2.14) 90 (25.57) 115 (38.85) 162 (55.67)
Mild 46 (12.30) 145 (41.19) 97 (32.77) 79 (27.15)
Moderate 244 (65.24) 97 (27.56) 80 (27.03) 43 (14.78)
Severe 76 (20.32) 20 (5.68) 4 (1.35) 7 (2.41)
Clinical response 215 (61.25) 244 (83.85) 244 (87.46)
Clinical remission 54 (14.44) 235 (66.78) * 212 (71.62) 241 (82.82)
Mayo endoscopic subscore
0 - remission 3 (0.80) 47 (20.98) 120 (41.24)
1 - mild 15 (4.00) 65 (29.02) 72 (24.74)
2 - moderate 136 (36.27) 81 (36.16) 55 (18.90)
3- severe 221 (58.93) 31 (13.84) 44 (15.12)
Hematocrit (%) 35.78 ± 5.76 36.77 ± 5.02* 37.98 ± 4.99* 38.59 ± 4.67*
Hemoglobin (g/dl) 11.72 ± 2.08 12.14 ± 1.87* 12.56 ± 1.82* 12.75 ± 1.66*
Albumin (g/dl) 3.59 ± 0.62 3.78 ± 0.50* 3.85 ± 0.47* 3.99 ± 0.48*
C-reactive protein (mg/dl) 20.22 ± 35.26 9.42 ± 20.9* 7.09 ± 17.12* 5.54 ± 14.29*
Calprotectin (μg/g) 1360.14 ± 1853.06 583.66 ± 843.26* 374.47 ± 521.87* 327.05 ± 589.45*
  1. Data presented as mean ± SD and n (%). *p < 0.05 compared to baseline. *Calculated by Student t test or Pearson, χ2 or Fisher´s exact test